Figures & data
Scheme 1 (a) PLGA-PEG-PLGA copolymer was dissolved into DOX liposomes suspension to form DOX-Lip-Gel, which was in a sol state at 25 °C. (b) DOX-Lip-Gel solution was injected peritumorally and transformed into a solid gel in situ at body temperature (37 °C), enabling the sustained release of DOX and significant inhibition of tumour growth.
![Scheme 1 (a) PLGA-PEG-PLGA copolymer was dissolved into DOX liposomes suspension to form DOX-Lip-Gel, which was in a sol state at 25 °C. (b) DOX-Lip-Gel solution was injected peritumorally and transformed into a solid gel in situ at body temperature (37 °C), enabling the sustained release of DOX and significant inhibition of tumour growth.](/cms/asset/87fbebcf-bb37-4812-a799-a2df1367f70f/ianb_a_1548470_sch0001_c.jpg)
Table 1. Chemical structure and chemical shift of PLGA-PEG-PLGA determined 1H NMR.
Table 2. Molecular parameters of the synthesized copolymer.
Figure 3 Particle size distribution of blank gel and blank Lip-Gel at different temperatures. The polymer concentration was 20 wt%.
![Figure 3 Particle size distribution of blank gel and blank Lip-Gel at different temperatures. The polymer concentration was 20 wt%.](/cms/asset/b3636dbc-b735-4f4c-a777-c239cc4fed80/ianb_a_1548470_f0003_c.jpg)
Figure 4 Viscosity analysis of blank gel (a) and DOX-Lip-Gel (b) with respect to temperature. The gel concentration was 20 wt%.
![Figure 4 Viscosity analysis of blank gel (a) and DOX-Lip-Gel (b) with respect to temperature. The gel concentration was 20 wt%.](/cms/asset/9814f4a2-7b1d-4bc2-8ad0-548e90e5db4e/ianb_a_1548470_f0004_c.jpg)
Figure 5 Blank Lip-Gel (a) and DOX-Lip-Gel (b) were in a sol state at room temperature (25 °C) and transformed into the solid gel at 37 °C.
![Figure 5 Blank Lip-Gel (a) and DOX-Lip-Gel (b) were in a sol state at room temperature (25 °C) and transformed into the solid gel at 37 °C.](/cms/asset/301231df-cb80-4862-bcf9-d969e79b7de2/ianb_a_1548470_f0005_c.jpg)
Figure 6 The degradation behaviour of the PLGA-PEG-PLGA based thermogel. The polymer solution (20 wt%) formed a gel in situ on Day 0 and degraded gradually with time.
![Figure 6 The degradation behaviour of the PLGA-PEG-PLGA based thermogel. The polymer solution (20 wt%) formed a gel in situ on Day 0 and degraded gradually with time.](/cms/asset/48cd64d1-29ab-4776-a271-a9131cca64ad/ianb_a_1548470_f0006_c.jpg)
Figure 7 HE-stained images of skin tissue after subcutaneous injection of thermogel (20 wt%) at predetermined time points. S: skin tissue; G: thermogel. The scale bar is 200 μm.
![Figure 7 HE-stained images of skin tissue after subcutaneous injection of thermogel (20 wt%) at predetermined time points. S: skin tissue; G: thermogel. The scale bar is 200 μm.](/cms/asset/5bee0d9b-fb62-470a-afa9-1cd54420b1e2/ianb_a_1548470_f0007_c.jpg)
Figure 8 In vitro cumulative DOX release profile from DOX-Gel, and DOX-Lip-Gel in PBS 7.4 solution at 37 °C. The experiment was done according to the tube method (n = 3).
![Figure 8 In vitro cumulative DOX release profile from DOX-Gel, and DOX-Lip-Gel in PBS 7.4 solution at 37 °C. The experiment was done according to the tube method (n = 3).](/cms/asset/976f953e-4467-4c77-8b7d-c3a57257ea94/ianb_a_1548470_f0008_c.jpg)
Figure 9 In vivo antitumor efficiency of different groups of saline, blank Lip-Gel, Free DOX, DOX-Lip, DOX-Gel and DOX-Lip-Gel on orthotopic tumor-bearing BABL/c mice model *p < 0.05, **p < 0.01, n = 6. (A) schematic of the time course of drug administration within the cycle of treatment; (B) tumor volume curves; (C) tumor weight of the different groups; (D) typical tumor images of all groups on Day 13; (E) body weight of different groups during the whole therapy.
![Figure 9 In vivo antitumor efficiency of different groups of saline, blank Lip-Gel, Free DOX, DOX-Lip, DOX-Gel and DOX-Lip-Gel on orthotopic tumor-bearing BABL/c mice model *p < 0.05, **p < 0.01, n = 6. (A) schematic of the time course of drug administration within the cycle of treatment; (B) tumor volume curves; (C) tumor weight of the different groups; (D) typical tumor images of all groups on Day 13; (E) body weight of different groups during the whole therapy.](/cms/asset/1da4a582-e000-4929-a563-496c0bfbda7e/ianb_a_1548470_f0009_c.jpg)
Table 3. Tumour inhibition parameters (n = 6).
Figure 10 (a) HE-stained images of tumour cross-sections of breast tumour-bearing BALB/c female mice taken on the Day 13 after administration of saline, blank Lip-Gel, free DOX, DOX-Lip, DOX-Gel, and DOX-Lip-Gel. (b) HE-stained images of heart tissue obtained after treated with saline, blank Lip-Gel, free DOX, DOX-Lip, DOX-Gel and DOX-Lip-Gel. Some typical inflammatory cells were denoted by red arrows, disorganization of myofibrillar arrays was denoted by blank arrows. The scale bar is 50 μm.
![Figure 10 (a) HE-stained images of tumour cross-sections of breast tumour-bearing BALB/c female mice taken on the Day 13 after administration of saline, blank Lip-Gel, free DOX, DOX-Lip, DOX-Gel, and DOX-Lip-Gel. (b) HE-stained images of heart tissue obtained after treated with saline, blank Lip-Gel, free DOX, DOX-Lip, DOX-Gel and DOX-Lip-Gel. Some typical inflammatory cells were denoted by red arrows, disorganization of myofibrillar arrays was denoted by blank arrows. The scale bar is 50 μm.](/cms/asset/c9cac963-3375-4bbe-981c-cc7c8b2266f0/ianb_a_1548470_f0010_c.jpg)